Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlconXSWX:ALC -1.65%70 Earnings per Share (Diluted) is CHF1.33 as of Mar. 2026. GuruFocus rates XSWX:ALC with a GF Score™ of 70/100 and a GF Value™ of CHF74.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 661 Medical Devices & Instruments companies, Alcon ranks worse than 53.86% on this metric.
Alcon's EPS (Basic) for the
three
months ended in Mar. 2026 was CHF0.31.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.33.
Alcon's EPS without NRI for the
three
months ended in Mar. 2026 was CHF0.67.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2.54.
During the past 12 months, Alcon's average EPS without NRIGrowth Rate was -3.60% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 5.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 18.50% per year.
During the past 10 years, Alcon's highest 3-Year average EPS without NRI Growth Rate was 36.90% per year. The lowest was -20.50% per year. And the median was 4.70% per year.
Alcon (XSWX:ALC) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Alcon Earnings per Share (Diluted) Related Terms
Alcon Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Alcon's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ALC vs ISRG, BDX, MDLN: Earnings per Share (Diluted) Comparison
For the Medical Instruments & Supplies subindustry, Alcon's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's PE Ratio distribution charts can be found below:
* The bar in red indicates where Alcon's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Alcon's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of CHF1.33 mean?
Alcon (XSWX:ALC) has a Earnings per Share (Diluted) of CHF1.33 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Alcon and its competitors. According to the industry distribution chart, Alcon ranks #356 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 53.9%.
Is Alcon's Earnings per Share (Diluted) too high?
Alcon's current Earnings per Share (Diluted) is CHF1.33. Based on the distribution chart, Alcon ranks #356 out of 661 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Earnings per Share (Diluted) compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #356 out of 661 companies for Earnings per Share (Diluted). This places Alcon in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.20, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current Earnings per Share (Diluted) is CHF1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF74.22, compared to a current price of CHF54.90 — trading 26% below its estimated fair value. The current Earnings per Share (Diluted) is CHF1.33. Alcon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Alcon (XSWX:ALC), the current Earnings per Share (Diluted) is CHF1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALC) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF54.90 is trading 26% below its estimated GF Value™ of CHF74.22.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALC:
Earnings per Share (Diluted): CHF1.33
GF Value™: CHF74.22 vs. price of CHF54.90 (26% below fair value)
No single metric tells the full story. See the XSWX:ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
70GF Score
Get the complete analysis for XSWX:ALC
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALC has been successfully added to your 
